{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.00","upperLimit":"29.02","value":"8.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"}],"units":"Participants"}],"title":"Cycle 1, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"23.92","value":"2.12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"title":"Cycle 2, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"}],"units":"Participants"}],"description":"AGI-16903 is a primary metabolite of enasidenib. Plasma AGI-16903 was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.","dispersionType":"Full Range","groups":[{"description":"Participants received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG000","title":"Phase 2: Enasidenib 100 mg QD"}],"paramType":"MEDIAN","populationDescription":"Participants who received enasidenib on Cycle 1, Day 1 or Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2, Day 1.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.","title":"Phase 2: Time to Maximum Concentration (Tmax) of AGI-16903 After Single and Multiple Oral Doses of Enasidenib","type":"SECONDARY","unitOfMeasure":"hours"}